Zevra Therapeutics ZVRA
NASDAQ ZVRA
$9.99 -0.19 (-1.87%)
At close: Oct 2, 2026 · 4:00 PM EDT

Zevra Therapeutics (ZVRA) Gains from Sales and Divestitures (2025 - 2026)

Updated

Zevra Therapeutics (ZVRA) reported Gains from Sales and Divestitures of $43.31 million for Q1 2026.

Analysis

Zevra Therapeutics (ZVRA) Gains from Sales and Divestitures (2025 - 2026) Analysis & Trends

For FY2025, Zevra Therapeutics posted Gains from Sales and Divestitures of $148.33 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Zevra Therapeutics 592.83 Mn -219.88 Mn 38.18 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 43.31 Mn
Jun 30, 2025 148.33 Mn
API Access

Zevra Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ZVRA&period=max&api_key=YOUR_API_KEY